A report from the Centers for Medicare and Medicaid Innovation confirmed that practices within the US Oncology Network and Tennessee Oncology participating in the Oncology Care Model (OCM) program have contributed significant savings to the agency.
Results from the Centers for Medicare and Medicaid Innovation (CMMI) report for the 8th performance period (PP8) of the Oncology Care Model (OCM) revealed that practices in the US Oncology Network and Tennessee Oncology that have participated in the program achieved high quality metrics and provided millions of dollars in savings to Medicare.
The OCM is a pilot program designed by CMMI to improve and better coordinate cancer care at the same or lower cost to Medicare. It is considered to be an integral part of Medicare’s ongoing effort to adopt a more value-based approach to health care.
The US Oncology Network
According to the report, all 14 of the participating practices within the Oncology Network improved patient care by achieving high quality measurement scores, resulting in a 100% Performance Multiplier for them. Combined, the practices saved Medicare about $54 million over the 6-month performance period to produce $197 million total savings since the OCM began in 2016, according to the organization.1 These 14 practices represent approximately 1 fourth of all providers participating in the program.
“We are extremely proud of the exceptional performance of all 14 of the practices in The US Oncology Network participating in the OCM and the cost savings they delivered to Medicare,” said Stuart Staggs, senior director of Strategic Programs for the US Oncology Network, in a statement.
During PP8, the US Oncology Network saw the lowest observed patient emergency department (ED) use since the start of the program, largely due to practices providing patients in need of immediate attention enhanced services, including nurse navigation, enhanced triage, telehealth services, or urgent care visits within the clinic.
"It is reassuring to see how well The Network practices are performing, as the OCM is a bridge to the future and an important first step in creating patient-centered cancer care that focuses on both quality and value,” said Judi Payne, director of value-based care transformation for the US Oncology Network.
Tennessee Oncology
Between the second half of 2019 and the first half of 2020, Tennessee Oncology saved Medicare over $5 million in total spending, doubling to over $10 million when removing care management payments, which do not contribute to patient expenditures. “As the cost of cancer care rises and patient financial toxicity worsens, savings such as this is more important than ever,” the organization wrote in a statement.2
Additionally, Tennessee Oncology received a 100% quality score during this period. The quality score comprised of measurements of patients paid and depression assessment and management, patient experience, reduction in unnecessary ED visits, and patient-centered end of life care through appropriate hospice utilization. Tennessee Oncology saw a 20% reduction in hospitalizations and a 27% reduction in ED visits PP8.
“To accomplish these results, we invested heavily in data analytics, created care navigation touch points, and incorporated electronic patient reported outcome monitoring to improve patient care. It is exciting to see these efforts working to improve quality and reduce cost for our patients,” said Leah Owens, executive director of care transformation at Tennessee Oncology.
The organization also made investments in building a palliative care program to help patients with management of symptoms and psychosocial support. During PP8, Tennessee Oncology saw palliative care referrals increase over 17%.
“Palliative care is an important component of the cancer care journey and has been shown to improve quality of life and even extend life for patients with cancer,” said Sandhya Mudumbi, MD, medical director of palliative care at Tennessee Oncology.
“Transforming to value-based care is not easy and takes time….The recent OCM report suggests the model did not succeed; however, our experience shows that for practices that commit to high value care….For Tennessee Oncology, we are finally here and excited to be on the cutting edge of care delivery innovation to improve patient care,” said Natalie Dickson, MD, president and chief medical officer at Tennessee Oncology.
Reference
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More